BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/24/2023 9:09:48 AM | Browse: 463 | Download: 1210
Publication Name World Journal of Clinical Cases
Manuscript ID 81204
Country France
ISSN 2307-8960 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Case Report
Article Title Gemcitabine-induced peripheral vascular disease and prolonged response in a patient with metastatic pancreatic adenocarcinoma: A case report
Manuscript Source Unsolicited Manuscript
All Author List Moinard-Butot Fabien, Poprawa Elodie, Schohn Anna, Pietro Addeo and Benabdelghani Meher
ORCID
Author(s) ORCID Number
Moinard-Butot Fabien http://orcid.org/0000-0002-5630-5220
Funding Agency and Grant Number
Corresponding Author Moinard-Butot Fabien, MD, Doctor, Doctor, Department of Medical Oncology, Institut de Cancérologie Strasbourg Europe, 17 Rue Albert Calmette, Strasbourg 67200, France. f.moinard-butot@icans.eu
Key Words Gemcitabine; Pancreatic cancer; Peripheral vascular disease; Prolonged tumor response; Case report
Core Tip Gemcitabine is known for vascular side effect. In this case, we report a vascular acrosyndrome that occurred during first-line with Gemcitabine for pancreatic adenocarcinoma. In this case, the patient experienced prolonged tumor response. Immunological phenomena could be responsible for this double effect.
Publish Date 2023-02-24 09:09
Citation Fabien MB, Elodie P, Anna S, Addeo P, Meher B. Gemcitabine-induced peripheral vascular disease and prolonged response in a patient with metastatic pancreatic adenocarcinoma: A case report. World J Clin Cases 2023; 11(6): 1372-1378
URL https://www.wjgnet.com/2307-8960/full/v11/i6/1372.htm
DOI https://dx.doi.org/10.12998/wjcc.v11.i6.1372
Full Article (PDF) WJCC-11-1372.pdf
Full Article (Word) WJCC-11-1372.docx